Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery.
We share your passion for science. Promega is committed to excellence in technologies for cellular therapy programs (e.g., CAR T cells and T cell receptor modifications) as well as immuno-oncology (e.g., LAG-3, TIM-3, ICOS, CD28, ADCC/ADCP and bi-specific mAbs). All assays are based on bright and sensitive firefly or NanoLuc luciferases. Let’s collaborate.
Immudex is a life science company providing solutions for cellular immune monitoring within immune-oncology, infectious disease, transplantation, and autoimmunity.
With our Dextramer® and dCODE Dextramer® technologies, we provide researchers and clinicians worldwide with reliable tools to accurately monitor the cellular immune response. Immudex products are used for T/B cell monitoring, TCR/BCR recognition and clonotype, gene expression and multi-omics, screening of TCR/BCR specificity, clinical immune monitoring (GMP), and much more.
Want to evaluate killing kinetics with physiologically relevant effector cell to target cell ratios? Concerned about the possible confounding effects of labeling your cells? Introducing Maestro ZHT from Axion BioSystems, the world’s most advanced impedance-based real-time cell analysis platform. Over minutes or weeks gain unprecedented access to the kinetics of your biology. Straightforward and easy to use, any researcher can now track immune cell-mediated killing in 96- and 384-well plates.
Pure MHC is a leading discovery and development company focused on identifying novel HLA peptide targets for oncology, infectious disease, and autoimmune indications. Using a proprietary methodology, Pure MHC qualifies and quantifies the surface presence of HLA peptide targets using primary tissues and provides them to partners for therapeutic development. De novo discovery projects as well as an assortment of well-profiled targets for CRC, NSCLC, glioblastoma, melanoma, ovarian, and breast cancers are available now.